CONTEXT The efficacy and safety of drug-eluting stents compared with bare-metal stents remains controversial in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). OBJECTIVE To compare stents eluting biolimus from a biodegradable polymer with bare-metal stents in primary PCI. DESIGN, SETTING, AND PATIENTS A prospectiv...

BACKGROUND Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. Early evaluations of new stents have used continuous end points that are presumed surrogates for restenosis, but the generalizability and power of such end points have not been examined systematically. METHODS AND RESULTS We examined the relationship between incremental changes in observed la...

Background—Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. Early evaluations of new stents have used continuous end points that are presumed surrogates for restenosis, but the generalizability and power of such end points have not been examined systematically. Methods and Results—We examined the relationship between incremental changes in observed late...

Treating multivessel disease in the era of coated stents: introduction N umerous reports in cardiology congresses and journals deal with multivessel treatment with percutaneous transluminal coronary angioplasty (PTCA) and stenting. Clinical practice, however, is very different with more than 90% of all percutaneous revascularisation procedures in Europe and the USA limited to single vessel trea...

The methodology in interventional cardiology has historically evolved from diagnostic coronary angiography to balloon angioplasty, to the use of bare metal stents (BmSs), to their refinement to drug-eluting stents with a durable polymer, and is now on the verge of drug-eluting stents with further developed drug delivery approaches such as reservoir technology and the use of bioresorbable polyme...

Commentary All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association. J udging from the large number of publications on the cost-effectiveness of drug-eluting coronary stents, there is an emerging international consensus that the price tag for the 2 commercially available drug-eluting stents is excessive (approximately $150...

CONTEXT Approval of drug-eluting coronary stents was based on results of relatively small trials of selected patients; however, in routine practice, stents are used in a broader spectrum of patients. OBJECTIVE To compare the first 2 commercially available drug-eluting stents-sirolimus-eluting and paclitaxel-eluting-for prevention of symptom-driven clinical end points, using a study design ref...

BACKGROUND Percutaneous coronary intervention (PCI) using drug-eluting stents significantly reduces the risk of restenosis in the general population. However, in patients on hemodialysis, adverse cardiac events are frequently seen even if treated with drug-eluting stents. Recent studies suggest that C-reactive protein (CRP) reflects vascular wall inflammation and can predict adverse cardiac eve...

OBJECTIVE Therapeutic strategies to provide local inhibition of mitogen mediated proliferation and migration of human coronary artery smooth muscle cells (CASMC) by means of drug-eluting stents have been shown to enable effective limitation of neointimal hyperplasia. However, currently available drug-eluting stents utilize compounds that may also adversely affect endothelial regrowth, thus poss...

Current drug-eluting stent (DES) technology is not optimized with regard to the pharmacokinetics of drug release, more research on the <span style="font-size: 12pt; color: #000000; font-style: normal; ...